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A Comparative Study of Three Different Types
of Stem Cells for Treatment of Rat Spinal Cord Injury
Jiri Ruzicka,*1 Lucia Machova-Urdzikova,*1 John Gillick,† Takashi Amemori,*
Nataliya Romanyuk,* Kristyna Karova,*‡ Kristyna Zaviskova,*‡ Jana Dubisova,*‡
Sarka Kubinova,* Raj Murali,† Eva Sykova,*‡ Meena Jhanwar-Uniyal,† and Pavla Jendelova*‡
*Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic
† New York Medical College, Valhalla, NY, USA
‡Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic

Three different sources of human stem cells—bone marrow-derived mesenchymal stem cells (BM-MSCs),
neural progenitors (NPs) derived from immortalized spinal fetal cell line (SPC-01), and induced pluripotent
stem cells (iPSCs)—were compared in the treatment of a balloon-induced spinal cord compression lesion in
rats. One week after lesioning, the rats received either BM-MSCs (intrathecally) or NPs (SPC-01 cells or iPSCNPs, both intraspinally), or saline. The rats were assessed for their locomotor skills (BBB, flat beam test, and
rotarod). Morphometric analyses of spared white and gray matter, axonal sprouting, and glial scar formation,
as well as qPCR and Luminex assay, were conducted to detect endogenous gene expression, while inflammatory cytokine levels were performed to evaluate the host tissue response to stem cell therapy. The highest
locomotor recovery was observed in iPSC-NP-grafted animals, which also displayed the highest amount of
preserved white and gray matter. Grafted iPSC-NPs and SPC-01 cells significantly increased the number of
growth-associated protein 43 (GAP43+) axons, reduced astrogliosis, downregulated Casp3 expression, and
increased IL-6 and IL-12 levels. hMSCs transiently decreased levels of inflammatory IL-2 and TNF-a. These
findings correlate with the short survival of hMSCs, while NPs survived for 2 months and matured slowly
into glia- and tissue-specific neuronal precursors. SPC-01 cells differentiated more in astroglial phenotypes
with a dense structure of the implant, whereas iPSC-NPs displayed a more neuronal phenotype with a loose
structure of the graft. We concluded that the BBB scores of iPSC-NP- and hMSC-injected rats were superior
to the SPC-01-treated group. The iPSC-NP treatment of spinal cord injury (SCI) provided the highest recovery
of locomotor function due to robust graft survival and its effect on tissue sparing, reduction of glial scarring,
and increased axonal sprouting.
Key words: Spinal cord injury (SCI); iPSC-derived human neural progenitors; Inflammatory response;
Human fetal neural stem cells; Human mesenchymal stem cells (hMSCs)

INTRODUCTION
The spinal cord is prone to injuries that result in damage
to the existing neural structures, leading to the destruction of locomotor and sensory pathways. This process
is followed by secondary damage processes, including a
local immune response, cavitation, glial scar formation,
and tissue atrophy, which enlarge the primary insult leading to impaired regeneration1,2. In recent years, stem cell
application after spinal cord injury (SCI) has generated
promising results. A variety of stem cells have shown
their potential for neurotransplantation. Transplanted stem
cells can either repair damaged tissue by replacing cells

destroyed during the primary insult or rescue cells in the
injured spinal cord by producing cytokines (interleukins)
and neurotrophic factors that facilitate regeneration or
revascularization, thus reducing glial scar formation.
Mesenchymal stem cells (MSCs) possess self-renewal
properties and are highly multipotent, giving rise to different cells of mesodermal origin such as adipocytes,
chondrocytes, and osteocytes3,4. Although MSCs are often
considered for stem cell therapy in SCI due to their antiinflammatory5, immunomodulatory6, and neuroprotective
properties7,8, their ability to functionally replace neurons
and glial cells remains highly debatable9. Furthermore,
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MSCs can secrete a whole set of neurotrophic, growth, and
angiogenic factors10–13, which exert a paracrine effect that
can increase neuronal survival, stimulate axonal regeneration and endogenous angiogenesis, and thus enhance
functional recovery. The possibility of autologous transplantation using MSCs has drawn the interest of many
scientific groups14–16. The majority of clinical studies
using MSC transplantation to treat SCI are in phase 1 or 2,
and their number is increasing, suggesting that despite
several drawbacks that still need to be addressed at basic
and preclinical levels, MSCs are considered potentially
beneficial for translational studies. The cells used in clinical trials are usually autologous to minimize the risk of
rejection and are often administered intrathecally (IT) to
avoid invasive surgical interventions.
Neural stem cells (NSCs) or neural progenitors (NPs)
are multipotent cells with the ability to differentiate into
neurons, oligodendrocytes, and astrocytes. NSCs are present in the adult as well as developing central nervous system (CNS) and can be isolated and expanded in vitro17–20
or prepared as differentiated derivatives from embryonic21,22
or induced pluripotent stem cells (iPSCs)23,24. The use
of NPs in repairing the damaged spinal cord is generally focused on the replacement of loss as well as on
trophic support of the remaining host nervous tissue25.
Functional improvement assessed by the Basso, Beattie,
and Bresnahan (BBB) locomotor scale has been reported
by several authors after the transplantation of NSCs in
SCI animals26–30. The source of implanted NSCs seems
to play an important role in defining their impact and
fate after SCI17,24,26,31. Since it is difficult to obtain fetal
tissue in the required quantity and quality, immortalized
cell lines have been developed using various techniques
worldwide. One of these approaches is conditionally
immortalized neuroepithelial stem cell lines, in which the
immortalizing gene is downregulated upon transplantation into the host tissue. The technology (c-mycERTAM)
employed to achieve conditional growth control is a
fusion protein composed of a growth-promoting gene
(c-myc) and a hormone receptor that is regulated by a
synthetic drug, 4-hydroxy-tamoxifen (4-OHT)32. One of
these cell lines, CTX0E03, has recently been approved
in the UK for a clinical phase II trial in stroke patients
(http://clinicaltrials.gov/show/NCT02117635).
iPSCs, originally described by Takahashi and
Yamanaka33, are derived from differentiated cells by
various reprogramming techniques by introducing specific transcription factors responsible for pluripotency.
Currently, a variety of methods have been developed to
derive iPSCs34,35. Human (h)NSCs derived from iPSCs
have already shown strong potential in the experimental
treatment of SCI24,28,31,36. Despite some unresolved issues
raising concern (such as teratoma formation, the immunogenicity of iPSC-derived cells37, and epigenetic factors),
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the first clinical trial using iPSCs in the damaged retina
has started in Japan38. Recently, the possibility of clinical
application of allogenic precursor cells derived from iPSC
lines is under investigation in nonhuman primates39,40.
In this investigation, we compared human bone marrowderived mesenchymal stem cells (BM-MSCs) manufactured under good manufacturing practices (GMPs) and
two types of NPs, including cells from a human conditional fetal spinal line (SPC-01, c-mycERTAM technology), and human induced pluripotent stem cell-derived
neural progenitors (iPSC-NPs) in the treatment of a
clinically relevant SCI model of balloon-induced spinal
cord compression in rats. The route of stem cell delivery
was also chosen according to the most appropriate clinical application of each stem cell type for SCI to provide
robust preclinical data for cell therapy translation. We
evaluated the effect of the application of the three cell
types on locomotor recovery (BBB, flat beam test, and
rotarod). Histological and immunohistochemical analyses were performed to assess white and gray matter (WM/
GM) sparing, axonal sprouting, and astrogliosis, while
the immunomodulatory effect of the implanted cells was
evaluated by an analysis of cytokines released after SCI
(Luminex assay). Quantitative polymerase chain reaction
(qPCR) was used to compare and evaluate the expression
of selected endogenous growth factors, caspase 3, and
M1- and M2-related macrophage genes after cell treatment in SCI.
MATERIALS AND METHODS
Cell Cultures
Human (h)MSCs were obtained based on the informed
consent from patients enrolled in the clinical trial
AMSC-DSD-001 and were provided by Bioinova Ltd.
(Prague, Czech Republic). Cells were prepared under
GMP conditions and supplied in 1.5 ml of cell suspension in Nunc (suspension of autologous MSC 3P). The
mononuclear fraction containing hMSCs was separated
from the bone marrow of healthy donors by gradient
separation using 25% Gelofusine (B. Braun, Melsungen,
Germany). The cells were expanded in minimal essential medium (MEM) Eagle alpha media (Lonza, Basel,
Switzerland), supplemented with 5% mixed allogeneic
thrombocyte lysate (Bioinova Ltd.) and 10 µg/ml gentamicin (Lek Pharmaceuticals, Ljublanja, Slovenia).
Cells (third passage) were analyzed using fluorescenceactivated cell sorting (FACS) (LSR II; BD Biosciences,
San Diego, CA, USA) and used for transplantation. The
cells were positive for CD73, CD105, CD90, and major
histocompatibility complex (MHC) class I, and negative
for CD45, CD14, CD34, CD16, CD3, CD19, CD80, and
MHC class II surface molecules. Control differentiation
protocol (adipogenic, osteogenic, and chondrogenic) was
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performed to confirm the multipotent potential of the
cells. Cell phenotyping was performed by Bioinova Ltd.
The human neural conditionally immortalized cell line
(SPC-01) was prepared according to the protocol described
in previous publications17,41. A retroviral vector encoding the immortalizing construct (c-mycERTAM) was
used to immortalize the cells from 10-week-old human
fetal spinal cords. Additionally, the SPC-01 cells were
transduced by green fluorescent protein (GFP). SPC-01
GFP+ cells were cultured in laminin-coated tissue culture
flasks in growth media, composed of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis,
MO, USA)/F12 supplemented with human serum albumin (HAS; 0.03%; Baxter Healthcare Ltd., Norfolk,
UK), human transferrin (100 µg/ml), L-glutamine (2 mM),
putrescine dihydrochloride (16.2 µg/ml), sodium selenite
(selenium; 40 ng/ml), human insulin (5 µg/ml), epidermal
growth factor (EGF; 20 ng/ml), progesterone (60 ng/ml),
and 4-OHT (100 nM) (all from Sigma-Aldrich), and
fibroblast growth factor (FGF; 10 ng/ml; PeproTech,
London, UK). The medium was changed three times per
week. SPC-01 GFP+ cells from passages 26–29 were used
in all experiments.
iPSC-NPs were prepared according to Polentes et al.42.
In order to derive the human iPSC line, a lentivirusmediated combination of octamer-binding transcription
factor 4 (OCT4), sex-determining region Y-box 2 (SOX2),
NANOG, and LIN28 human cDNA33 (prepared plasmid
from Addgene, Cambridge, MA, USA) was used for
transduction of female (IMR90) human fetal lung fibroblasts (ATCC; Manassas, VA, USA). Clone selection,
validation of the iPSC line, and derivation of neuronal
progenitors are described in detail42. Cells were routinely
cultured in tissue culture flasks coated with laminin (10 µg/
ml in DMEM/F12) and poly-L-ornithine (0.002% in distilled water), both from Sigma-Aldrich. Growth medium
comprising DMEM/F12 and Neurobasal medium (1:1),
N2 supplement (1:100), B27 supplement (1:50; GIBCO,
Life Technologies, Grand Island, NY, USA), L-glutamine
(2 mM; Sigma-Aldrich), penicillin and streptomycin
(50 U/ml; GIBCO), EGF (10 ng/ml), FGF (10 ng/ml),
and brain-derived neurotrophic factor (BDNF; 20 ng/ml;
PeproTech) was changed three times per week. A 7-day
process of predifferentiation in the same medium, except
for the omission of FGF and EGF, was used prior to
transplantation of iPSC-NPs.
Animals
Ten-week-old male Wistar rats (Anlab, Prague, Czech
Republic) (n = 225) with body weights of 300 ± 15 g were
used. The rats were housed in pairs and maintained in
environmentally controlled rooms (22°C–24°C) with a 12-h
light/dark cycle. Seven days after injury, all rats were
implanted either IT with MSCs (n = 47) or saline (n = 38),
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or intraspinally (IS) at the level of SCI with SPC-01 cells
(n = 50), iPSC-NPs (n = 49), or saline (n = 41). Animals
used for cytokine assay (sacrificed 10, 14, and 28 days
after injury) and gene expression assay (sacrificed 10 and
28 days after injury) were not used for behavioral evaluation. At each time point, five rats per group were allocated for protein expression studies (Luminex, Austin,
TX, USA) and for qPCR. The second group of rats
(saline, n = 16; MSCs, n = 22; SPC-01, n = 25; iPSC-NPs,
n = 24) was used for behavioral, histological, immunohistochemical, and 2-month qPCR studies. Histological and
immunohistochemical evaluation was performed either
on longitudinal spinal sections [saline (IS + IT), n = 7 + 6;
MSCs, n = 11; SPC-01, n = 14; iPSC-NPs, n = 11] or on
cross-sections [saline (IS + IT), n = 8 + 7; MSCs, n = 7;
SPC-01, n = 8; iPSC-NPs, n = 10] 2 months after grafting.
Preliminary experiments were performed to determine
the cell survival of the transplanted cells (MSCs, n = 4;
SPC-01, n = 3; iPSC-NPs, n = 3) 2 weeks following their
administration. All experiments were performed in accordance with the European Communities Council Directive
on September 22, 2010 (2010/63/EU) regarding the use
of animals in research and were approved by the ethics
committee of the Institute of Experimental Medicine,
Academy of Sciences of the Czech Republic.
SCI and Cell Transplantation
A balloon-induced spinal cord compression lesion was
used as the model of SCI in rats43. The surgical procedures
were performed under sterile conditions. After the induction of anesthesia (3.5 vol%; Forane; AbbVie, Prague,
Czech Republic) and an intramuscular injection of analgesic (Rimadyl 50 µl; Zoetis, Prague, Czech Republic),
1 cm of 2-French Fogarty catheter was inserted into the
epidural space through a laminectomy at T10. Body temperature was maintained at 37°C during the entire surgical procedure. Spinal cord compression was induced by
inflation of the balloon with 15 µl of saline for 5 min at
the T8 spinal level and then the catheter was emptied,
removed, and the wound was sutured in anatomical layers.
Gentamicin (5 mg/kg; Sandoz, Prague, Czech Republic)
was given intramuscularly within 10 days to prevent
postsurgical infection. Retention of urine was prevented
by manual bladder expression performed twice per day.
Seven days after SCI, hMSCs (5 ´ 105/50 µl saline) were
injected into the subdural space through the L5–L6 intervertebral space according to De la Calle and Paino44. NPs,
SPC-01 cells (5 ´ 105/5 µl saline), or iPSC-NPs (5 ´ 105/
5 µl saline) were implanted in situ into the lesioned tissue
at the area of Th8–9 according to Amemori et al.26. Control
rats for the MSC group were injected with 50 µl of saline
into the L5–L6 intervertebral space. Control animals for
the SPC and iPSC-NP groups were injected with 5 µl
of saline into the lesioned tissue. A daily injection of
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immunosupressants [cyclosporine A (Sandimmune; 10 mg/
kg; Novartis, Prague, Czech Republic) and azathioprine
sodium (Imuran; 2 mg/kg; GlaxoSmithKline, Prague,
Czech Republic)] was used to prevent the rejection of the
cell transplants and was performed in all groups of animals (including controls).
Behavioral Assessment
BBB Test. Basic locomotor functions were evaluated
using the BBB open field test45. Two independent examiners scored the locomotor performance of experimental
rats placed into a circular arena on a scale of 0–21 for
approximately 4 min once a week, starting from the first
week after SCI.
Flat Beam Test. The flat beam test was used to assess
motor function and forelimb–hindlimb coordination. The
central part of the beam (1 m long) was used to evaluate the walking distance and velocity. The latency and
the trajectory were recorded for a period of 60 s using a
video-tracking system (TSE-Systems Inc., Bad Homburg,
Germany). After pretraining, testing was performed twice
per day for 3 consecutive days. The rats were examined
before surgery and then every week from the second week
after lesion induction. The rats were scored on a 5-point
scale modified from Goldstein46, reflecting their ability to
cross the beam.
Rotarod Test. Motor function and the coordination of
the hindlimbs were examined in a four-lane rotarod unit
(Ugo Basile, Comerio, Italy). Rats underwent 5 consecutive days of training prior to the injury. In training mode,
the rod was accelerated from 5 to 10 rpm over a period of
5 min. Lesioned rats were allowed to stay on the rod at a
fixed speed of 5 rpm during a 1-min observation period.
The latency to fall from the rotating rod was automatically recorded. The test was performed before surgery
and 2, 4, 6, and 8 weeks after the injection of stem cells
(MSCs, SPC-01, or iPSC-NPs) or saline.
Plantar Test. The plantar test was performed using an
Ugo Basile test apparatus (Ugo Basile). A radiant thermal stimulus was applied to the plantar surface of the
paws, and the latency of the paw withdrawal response
was measured. Each paw was stimulated five times. The
test was performed before SCI and then weekly after SCI
throughout the whole survival period. Hyperalgesia, as a
response to the thermal stimulus, was defined as a significant decrease in the withdrawal latency.
Immunohistochemical and Histological Staining
To investigate the presence of viable stem cells at the
site of injury, MSCs were labeled with the long-term
tracer carboxyfluorescein diacetate succinimidyl ester
(CFDA-SE) before transplantation. Two (MSCs, n = 4;
SPC-01, n = 3; and iPSC-NPs, n = 3) and 8 (MSCs, n = 18;
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SPC-01, n = 22; and iPSC-NPs, n = 21) weeks after transplantation, the rats were transcardially perfused with 4%
paraformaldehyde (PFA) (Penta s.r.o., Prague, Czech
Republic) in phosphate-buffered saline (PBS), and their
spinal cords were removed. A 2-cm-long segment of the
spinal cord was dissected between 1 cm cranial and 1 cm
caudal to the injury epicenter. To monitor the survival,
migration, and differentiation of the transplanted cells,
serial longitudinal sections of the spinal cord (14 µm) were
cut through the areas of interest, using a Leica CM1850
cryostat (Leica Microsystems GmbH, Vienna, Austria).
For assessing glial scar formation, axonal sprouting, and
the extent of spared WM/GM, tissue samples from the
9-week survival period (e.g., 8 weeks after cell transplantation) were embedded in paraffin and cut into cross sections (5-µm thickness).
To identify human cells transplanted into the rat spinal
cord, antibodies directed against human nuclei [HuNu
(Millipore, Billerica, MA, USA), Ku80, and human mitochondrial marker MTC02 (both Abcam, Cambridge,
UK)] were used for all cells in addition to GFP labeling of the SPC-01 cells. To follow the fate of the transplanted stem cells and their interaction with the host
tissue, antibodies directed against nestin (Millipore), glial
fibrillary acidic protein (GFAP; Sigma-Aldrich), bIIItubulin (both Sigma-Aldrich), Nkx6.1 (DSHB, Iowa
City, IA, USA), oligodendrocyte transcription factor 2
(Olig2), microtubule-associated protein 2 (MAP2; both
Abcam), and doublecortin (DCX; Santa Cruz Biotechnology, Heidelberg, Germany) were used.
To estimate the number of implanted NPs (iPSCNPs and SPC-01) 2 months after implantation, every
sixth longitudinal spinal cord section (14-µm thickness)
was chosen. Imaging of the whole graft area per section
was performed (Observer D1 microscope; Carl Zeiss,
Weimar, Germany). The surviving human cells were
recognized using HuNu staining, and the analysis was
performed using ImageJ software [National Institutes
of Health (NIH), Bethesda, MA, USA]. The total number of human cells that survived was estimated according to the spinal cord volume in which the cells were
found (number of HuNu+ sections multiplied by six).
The percentage of surviving transplanted cells was calculated by dividing the estimated total number of surviving cells by the total number of transplanted cells
(5 ´ 105). Data are presented as an average per transplanted group.
To visualize primary antibody reactivity, appropriate
secondary antibodies were used: goat anti-mouse immunoglobulin G (IgG) conjugated with Alexa Fluor 488, as
well as goat anti-rabbit IgG conjugated with Alexa Fluor
594 (Molecular Probes, Eugene, OR, USA). The histological and immunohistochemical evaluations were carried out using a ZEISS AXIO Observer D1 microscope
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GFAP Staining. For immunohistochemical analysis of
glial scaring, a CY3-conjugated primary antibody against
GFAP was used on serial cross sections around the central
lesion cavity 9 weeks after SCI. For each sample, 15 sections were selected at 1-mm intervals along the craniocaudal axis including the lesion center on the eighth slide.
Images of the spinal cord were taken with an Axioskop 2
plus microscope. The number of protoplasmic astrocytes
per slice and the area of GFAP positivity surrounding the
main lesion cavity were analyzed using ImageJ.

Kit (Roche, Penzberg, Germany) following the manufacturer’s recommendations. RNA amounts were quantified
using a spectrophotometer (NanoPhotometerTM P-Class,
Munchen, Germany). The isolated RNA was reverse transcribed into cDNA using Transcriptor Universal cDNA
Master (Roche) and a thermal cycler (T100™ Thermal
Cycler; Bio-Rad, Hercules, CA, USA). The qRT-PCRs
were performed using cDNA solution, FastStart Universal
Probe Master (Roche), and the following TagMan Gene
Expression Assays (Life Technologies, Carlsbad, CA,
USA): Gapdh/Rn01775763_g1, Olig2/Rn01767116_m1,
SORT1 (NT-3)/Rn01521847_m1, Fgf2/Rn00570809_m1,
Casp3/Rn00563902_m1, Gfap/Rn00566603_m1, Gap43/
Rn01474579_m1, Vegfa/Rn01511601_m1, Bdnf/Rn0253
1967_s1, Cntf/Rn00755092_m1, nerve growth factor
(Ngf)/Rn01533872_m1, Irf5/Rn01500522_m1, CD86/
Rn00571654_m1, Mrc1/Rn01487342_m1, and CD163/
Rn01492519_m1.
The qRT-PCR was carried out in a final volume of
10 µl containing 25 ng of extracted RNA. Amplification
was performed on a StepOnePlus™ real-time PCR cycler
(Life Technologies). All amplifications were run under the
same cycling conditions: 2 min at 50°C, 10 min at 95°C,
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C.
All samples were run in duplicate, and a negative control was included in each array. Relative quantification of
gene expression was determined using the DDCt method.
The results were analyzed with StepOnePlus® software.
The gene expression levels were normalized based on
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as a reference gene; control samples with vehicle (PBS)
transplantation were used as a calibrator. The statistical
significance of the differences between the transplanted
and control (saline) groups was determined on DCt values
level using a one-way analysis of variance (ANOVA) test
with a post hoc pair-to-pair test. Differences were considered statistically significant if p < 0.05. Data are expressed
as the mean ± the standard error of mean (SEM).

qPCR
The expression of rat target genes [neurotrophin-3
(NT-3); sortilin 1 (Sort1)], FGF2, mannose receptor C type
1 (MRC1), interferon regulatory factor 5 (IRF5), OLIG2,
GAP43, CASP3, GFAP, vascular endothelial growth factor A (VEGFA), and ciliary neurotrophic factor (CNTF)]
was studied using quantitative real-time polymerase chain
reaction (qRT-PCR) at 10 and 28 days and at 2 months
after stem cell transplantation [MSCs, n = 5 per time point;
SPC-01, n = 5 per time point; iPSC-NPs, n = 5 per time
point; saline (IT + IS), n = 5 + 5 per time point]. The paraffin
sections of injured spinal cord from the region of the lesion
epicenter (center of the lesion + 2 cranial and 2 caudal sections) were taken for the study. RNA was isolated from
tissue cross sections using the High Pure RNA Paraffin

Cytokine Evaluation
The levels of cytokines were measured to analyze
the effects of the transplantation of various stem cells
(MSCs, SPC-01, and iPSC-NPs) on inflammation in
the region of the lesion 10, 14, and 28 days after SCI
(n = 5 per time point in all groups). A piece of the spinal cord at the site of the lesion was dissected out and
incubated in cell media [DMEM supplemented with
10% fetal bovine serum (FBS); Gibco, Thermo Fisher
Scientific, Waltham, MA, USA] and 0.2% primocin (Life
Technologies, Thermo Fisher Scientific)47–49. To measure the levels of inflammatory cytokines, the medium
was collected after a 24-h incubation period. Cytokine
levels were determined using a customized Milliplex
inflammatory cytokine kit (Millipore) and Magpix

(Carl Zeiss). Either Wizzard (Carl Zeiss), or ImageJ
programs were used for image analysis of the histological and immunohistochemical staining. Excel 2010
(Microsoft, Redmond, WA, USA) and CorelDRAW ´5
(Corel Corporation, Ontario, Canada) were used to create
the graphics.
Cresyl Violet–Luxol Staining. To distinguish the spinal
cord WM/GM, cresyl violet (CV) and Luxol fast blue (both
Sigma-Aldrich) staining were used on serial cross sections.
For each sample, 15 sections were selected at 1-mm intervals along the craniocaudal axis, including the lesion center on the eighth slide. Images of the spinal cord were taken
with an Axioskop 2 plus microscope (Zeiss, Oberkochen,
Germany). The amounts of spared gray and white matter
were analyzed using ImageJ software.
GAP43 Staining. For immunohistochemical analysis
of axonal sprouting, a primary antibody against GAP43
(Millipore) was used on serial cross sections around the
central lesion cavity 9 weeks after SCI. For each sample, 15 sections were selected at 1-mm intervals along
the craniocaudal axis, including the lesion center on the
eighth slide. Images of the spinal cord were taken with
an Axioskop 2 plus microscope. The number of GAP43+
fibers per slide was manually counted. The graphical presentation of these results shows the average number of
GAP43+ fibers per slide in percentage, when compared
with the saline group, which was set to 100%.
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instrumentation software (Thermo Fisher Scientific). Rat
cytokine Luminex custom 8-plex kits [for IL-1b, IL-4,
IL-2, IL-6, IL-12p70, macrophage inflammatory protein
1a (MIP-1a), tumor necrosis factor-a (TNF-a), and regulated on activation, normal T-cell expressed and secreted
(RANTES)] were used for customized bead assays. The
assays were performed in 96-well filter bottom plates
according to the manufacturer’s protocol (Thermo Fisher
Scientific). Antibody-conjugated beads were used at a
concentration of 5,000 beads per marker in accordance
with the manufacturer’s protocol. Biotinylated detection antibodies were added together with streptavidin–
RPE (streptavidin–R-phycoerythrin) (both from Thermo
Fisher Scientific), and then the levels of cytokines were
measured on a Luminex xMAP 200 system and analyzed
using the Magpix instrumentation software. To calculate
the concentration of each cytokine, the raw data, consisting of mean fluorescence intensity (MFI), were used.
A four- or five-parameter logistic fit curve was generated for each cytokine from seven standards. The lowest standard, which was at least three times above the
background, was used to determine the lower limit of
quantification (LLOQ).The calculation of the LLOQ was
performed using a specific calculation by subtracting the
MFI of the background (diluent) from the MFI of the
lowest standard concentration, and then back calculating
the concentration from the standard curve. The results
are presented as the percentage change from nonlesioned
tissue for each time point.
Statistical Analyses
All data are presented in graphs as the mean ± SEM.
The statistical significance of differences between the
MSC- , SPC-01-, iPSC-NP-, and saline-injected groups
was determined using either one-way ANOVA or twoway ANOVA in the case of a second factor (time). In the
case of repeated measurements (behavioral tests) or the
spatial distribution of the treatment effect (gray/white
matter sparing, glial scar distribution), two-way repeated-measures (RM) ANOVA was used. The Student–
Newman–Keuls (SNK) post hoc pair-to-pair test was
used to specify for which groups and at which time points
were the changes significant (all in Sigmastat 3.1; Systat
Software Inc., San Jose, CA, USA). Differences were
considered statistically significant if p < 0.05.
RESULTS
Cell Fate and the Pattern of Discrete
Differentiation Following Stem Cell Implantation
The survival of IT (MSCs) and IS (SPC-01 and iPSCNPs) grafted cells was evaluated 2 weeks and 2 months
postimplantation, respectively. Only a few MSCs were
observed partially attached to the dorsal spinal cord
surface (Fig. 1A) 2 weeks after application, and none
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were detected 2 months postgrafting. In contrast, noticeably high numbers of neural precursors derived from
either SPC-01 cells (16 ± 3%) or iPSC-NPs (11 ± 3%)
were detected around the injection site at 2 months after
implantation (Fig. 1B and C). Both types of human NPs
2 months after implantation remained rather immature.
SPC-01 cells were predominantly positive for GFAP
(Fig. 1D) or for early neural markers such as nestin
(Fig. 1E), olig2 (Fig. 1F), and Nkx6-1. Most of the
iPSC-NPs were positive for bIII-tubulin (Fig. 1G), Map2
(Fig. 1H), and DCX (Fig. 1I), with only some of the
grafted cells being GFAP+ (Fig. 1J) (for more details, see
http://www.iem.cas.cz/en/research/departments/tissue_
culture/supplementary_documents.html).
Functional Recovery From SCI Following
Stem Cell Implantation
The BBB test was performed once a week after lesion
induction to evaluate hindlimb locomotor recovery. All
stem cell-treated rats performed significantly better when
compared with saline-treated animals. Additionally,
iPSC-NP- and MSC-injected rats were superior to the
SPC-01-treated group (two-way RM ANOVA, treatment;
p < 0.001; for p values of post hoc pair-to-pair test, see
http://www.iem.cas.cz/en/research/departments/tissue_
culture/supplementary_documents.html) (Fig. 2A).
The recovery of advanced locomotor function was
evaluated using the flat beam test. In this test, rats grafted
with iPSC-NPs showed the greatest degree of improvement when compared to the saline-treated animals as well
as other stem cell groups. However, probably because of
the severe injury and higher level of coordination and
muscle strength that is needed for the flat beam test, not
all cell-treated groups showed significant improvement
when compared to saline-injected rats (two-way RM
ANOVA, treatment; p < 0.001; for p values of post hoc
pair-to-pair test, see http://www.iem.cas.cz/en/research/
departments/tissue_culture/supplementary_documents.
html) (Fig. 2B).
The time score in the flat beam test reflected the time
it took to cross the beam within a 60-s test period; the test
was performed starting from the third week onward after
treatment. The iPSC-NP-treated rats showed a marked
ability to cross the beam in a shorter time interval than
any other group and displayed progressive improvement
over the experimental period; no other group showed a
significant improvement during the measurement period
(two-way RM ANOVA, treatment; p < 0.001; for post hoc
pair-to-pair test p values, see http://www.iem.cas.cz/en/
research/departments/tissue_culture/supplementary_
documents.html) (Fig. 2C).
To determine long-term weight support and endurance and footstep coordination, the rotarod test was
used. As expected, because of the difficulty of the test,
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Figure 1. Survival of implanted stem cells and differentiation pattern of SPC-01 and iPSC-NP cells following their implantation
after SCI. Only a few MSCs were detected on the spinal cord surface 2 weeks after application (A), while SPC-01 cells (B) and
iPSC-NPs (C) survived robustly for at least 2 months after implantation. Arrows mark the attached MSCs. Insets (A1–A3) show
the MSC morphology. Staining for MTCO2 (B, C) or CFDA-SE (A) was used to detect the implanted cells in the injured spinal
cord. The differentiation patterns of SPCs (D–F) and iPSC-NPs (G–J) demonstrated that the majority of SPCs differentiated into
astrocytes (D) or remained immature (E, F), while on the other hand transplanted iPSC-NPs expressed mainly neuronal markers
(G–I) and less astrocytic markers (J). (D), (F)–(H), and (J) were taken from the edge of the graft, (E) is from the graft center, and
(I) shows cell migration into the host tissue (Orto images are online in additional files http://www.iem.cas.cz/en/research/depart
ments/tissue_culture/supplementary_documents.html). Scale bars: 300 µm (A), 500 µm (B, C), 20 µm (A1, A2, A3, D–J). CFDA-SE,
carboxyfluorescein diacetate succinimidyl ester; MTC02, anti-mitochondria antibody; HuNu, human nuclei (all green); DAPI, 4¢,6diamidin-2-fenylindol (blue); MSC, mesenchymal stem cell; iPSC-NPs, human induced pluripotent stem cell-derived neural precursors; OLIG2, oligodendrocyte transcription factor 2; DCX, doublecortin; SPC, spinal fetal cell; SCI, spinal cord injury.
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Figure 2. Locomotor and sensory recovery following stem cell transplantation after SCI. Recovery from SCI after the administration of MSCs, SPC-01 cells, or iPSC-NPs. The locomotor ability of saline- or stem cell-treated rats was assessed using the BBB
(A), flat beam (B), time score (C), and rotarod tests (D). All treated animals showed significantly higher performances in the openfield BBB test in comparison with saline controls (A). Additionally, the iPSC-NP and MSC groups demonstrated significantly higher
performances compared to the other treatment group. In tests requiring more advanced locomotor skills, such as the flat beam test
(B), all treated groups showed a significant difference when compared with the saline group, but with a dominance of iPSC-NP. For
the rotarod test (D), for which body weight-supported stepping is essential, a stable but insignificant trend of iPSC-NPs in higher
performance was observed. Thermal nociception was assessed using the plantar test (E) after stem cell or saline transplantation, and
no additional hyperalgesia after grafting of stem cells was observed. *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus
SPC-01; ¤p < 0.05 versus iPSC-NPs. For p values, see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_
documents.html. BBB, Basso, Beattie, and Bresnahan test; BI, before injury; MSC, mesenchymal stem cell; iPSC-NPs, human induced
pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord injury; TX, stem cell transplantation.

no significant differences in stem cell-treated rats were
observed when compared with saline-treated animals
(two-way RM ANOVA, treatment; p > 0.05; for p values
of post hoc pair-to-pair test, see http://www.iem.cas.cz/
en/research/departments/tissue_culture/supplementary_
documents.html) (Fig. 2D).

Changes in the sensory function of the hindlimb after
SCI (increased sensitivity to a thermal stimulus) were
determined using the plantar test apparatus (Ugo Basile).
Hyperalgesia is generally correlated to the pathological
state induced by SCI as well as to sensory function adaptation over time. All stem cell-treated animals were similar
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to the saline-treated group, which implies that no additional hyperalgesia appeared following stem cell transplantation (two-way RM ANOVA, treatment; p > 0.1; for
p values of post hoc pair-to-pair test, see http://www.iem.
cas.cz/en/research/departments/tissue_culture/supple
mentary_documents.html) (Fig. 2E).
Estimation of White and Gray Matter Sparing
Following Stem Cell Treatment After SCI
The area of spared WM/GM in the spinal cord (µm2
per cross section) was measured on 15 CV–Luxol-stained
spinal cross sections 2 months after injury. The values
presented in Figure 3A are given in relation to the areas
measured in saline-treated control animals, which were
set as 100%. Despite the observed impact of all stem
cell types on WM/GM sparing, only the implantation of
iPSC-NPs showed a statistically significant preservation
of WM/GM, in comparison with saline-treated as well as
other stem cell-treated animals (two-way RM ANOVA,
treatment; p < 0.001; for p values of post hoc pair-to-pair
test, see http://www.iem.cas.cz/en/research/departments/
tissue_culture/supplementary_documents.html) (the statistical significance within the link) (Fig. 3A, a1–a3).
Astrogliosis and Morphological Changes in GFAP+
Cells Following Stem Cell Transplantation
The area of the glial scar surrounding the central lesion
was measured on 15 GFAP–cyanine 3 (CY3)-stained spinal cord cross section slices 2 months after injury. The
values shown in Figure 3B are presented as the percentage
of the GFAP+ area compared to the total tissue area. All
stem cell-treated groups had significantly smaller GFAP+
volume compared to saline-treated animals, when calculated as a sum of area of single slices. Additionally, rats
grafted with SPC-01 cells or iPSC-NPs had significantly
smaller GFAP+ volume in comparison with rats receiving
MSCs (two-way RM ANOVA, treatment; p < 0.001; for
p values of post hoc pair-to-pair test, see http://www.iem.
cas.cz/en/research/departments/tissue_culture/supple
mentary_documents.html) (Fig. 3B, b1, b2). Moreover,
the effect of stem cells on GFAP phenotype after SCI was
shown. Rats injected with saline, MSCs, or SPC-01 cells
had a significantly higher number of protoplasmic astrocytes per slice in comparison with the iPSC-NP group
(two-way RM ANOVA, treatment; p < 0.05; for p values
of post hoc pair-to-pair test, see http://www.iem.cas.cz/
en/research/departments/tissue_culture/supplementary_
documents.html) (Fig. 3B, b3, b4).
Determination of Axonal Sprouting Following
Stem Cell Implantation After SCI
The number of GAP43+ fibers was calculated in cross
sections of injured spinal cords 2 months after injury. The
values presented in Figure 3C are given in relation to
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the value found in saline-treated animals, which was set
as 100%. A higher number of GAP43+ fibers in the spinal cord cross sections of both types of NP-transplanted
rats were observed, when compared to both salineand MSC-treated animals (two-way RM ANOVA, treatment; p < 0.05; for p values of post hoc pair-to-pair
test, see http://www.iem.cas.cz/en/research/departments/
tissue_culture/supplementary_documents.html) (Fig. 3C,
c1–c3).
M1 and M2 Macrophage-Related Gene Expression
in Response to Stem Cell Transplantation After SCI
The expression of genes related to the macrophage
phenotypes M1 (IRF5 and CD86) and M2 (MRC1 and
CD163) was determined by qRT-PCR from spinal cord
samples taken from the lesion site 10 and 28 days after
cell transplantation. Ten days after SCI, spinal cord tissue treated with MSCs revealed the upregulation of IRF5
( p < 0.05) and MRC1 when compared to the control tissue. Gene expression remained unaltered in samples
taken from the SPC-01-treated spinal cords. On the other
hand, iPSC-NP-treated rats showed a downregulation of
CD86 and CD163, markers of M1 and M2 macrophages,
respectively (Fig. 4A, a1). Twenty-eight days after grafting, all of the studied genes related to M1 and M2 macrophages were upregulated; however, this upregulation
remained statistically insignificant (post hoc pair-to-pair
test; for p values, see http://www.iem.cas.cz/en/research/
departments/tissue_culture/supplementary_documents.
html) (Fig. 4A, a2).
Expression of Intrinsic Genes After
Stem Cell Treatment of SCI
The relative expression of rat genes related to growth
factors [SORT1 (NT-3), FGF2, CNTF, and BDNF], apoptosis (Casp3), vascularization (VEGFA), axonal sprouting (GAP43), astrogliosis (GFAP), and oligodendrocytes
(OLIG2) following stem cell transplantation was determined 10 (Fig. 4B, b1) and 28 (Fig. 4B, b2) days and
2 months (Fig. 4B, b3) after SCI. Ten days after SCI
(3 days after grafting), animals with implanted MSCs
displayed an elevated expression of all genes of interest as a strong but insignificant trend. Similar levels of
gene expression in the MSC-treated group continued
after 28 days, apart from the downregulated expression of Casp3. Two months after SCI, the MSC group
showed a significant downregulation of BDNF, VEGF,
and NGF in comparison with the saline- and both
NP-treated groups. The transplantation of SPC-01 cells
and iPSC-NPs did not cause any notable changes in gene
expression at any of the time points; however, a gradual
alteration in gene expression, mostly pertaining to genes
related to recovery processes, was observed at 28 days as
well as 2 months after SCI (Fig. 4B, b2, b3). The greatest
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upregulation of gene expression was found for FGF2; however, this change was not significant (post hoc pair-to-pair
test; for p values, see http://www.iem.cas.cz/en/research/
departments/tissue_culture/supplementary_documents.
html) (Fig. 4B, b1 and b2).
Changes in Cytokine Profiles After
Stem Cell Treatment Following SCI
To determine the inflammatory response following
treatment with MSCs, SPC-01 cells, or iPSC-NPs, the
levels of cytokines (MIP-1a, IL-4, IL-1b, IL-2, IL-6,
IL-12p70, TNF-a, and RANTES) were assayed at 10, 14,
and 28 days after SCI. The levels of MIP-1a, IL-2, and
TNF-a were decreased relatively to those of the salinetreated controls at 10 days post-SCI in all three stem cell
groups and persisted through day 14. At day 28 in the MSC
group, the MIP-1a, IL-2, and TNF-a levels increased
in comparison with those of other groups. The levels of
RANTES remained significantly depressed below saline
control levels in the SPC-01 and iPSC-NP groups, while
its concentration was above control levels in the MSC
group. IL-4 levels were reduced in MSC-treated animals
at day 10 and increased insignificantly at day 28. In contrast, levels of IL-4 in both NP groups gradually increased
when compared to that of the saline group. The levels
of IL-1b were insignificantly lowered compared to that
of the controls at day 10 in MSC and SPC-01 groups,
and significantly in the case of the iPSC-NP group.
At 14 and 28 days after SCI, levels of IL-1b remained
similar to those of the saline-treated group, apart from
an increase in the SPC-01 group on day 14 after SCI.
IL-6 and IL-12p70 levels were noticeably higher in both
NP groups compared to the control and MSC groups.
This pattern continued throughout the whole experimental period (post hoc pair-to-pair test; for p values, see
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http://www.iem.cas.cz/en/research/departments/tissue_
culture/supplementary_documents.html) (Fig. 4C, c1–c3).
DISCUSSION
This investigation demonstrates the effectiveness of
MSCs and two NPs derived from either human fetal spinal cord precursors (in our study SPC-01) or from iPSCs
(iPSC-NPs) in the cell therapy of SCI. In detail, it provides a description of the different mechanisms underlying their support of SCI recovery, in particular the
survival and differentiation patterns, as well as the antiinflammatory action of these cells, which together govern
the repair and recovery process.
The intrathecal application of MSCs and the intraspinal application of SPC-01s and iPSC-NPs were chosen
as the routes of delivery. Stem cell properties in vivo
and their impact on behavior recovery and the physiological changes related to SCI are closely associated
with the mode of their administration, that is, local or
systemic18,50,51. Nevertheless, meta-analyses of behavioral recovery after MSC application in experimental
rat models of SCI failed to detect any statistically significant differences in locomotor recovery between intraparenchymal, intrathecal, or intravenous administration14.
Intrathecal administration of MSCs has been proposed
to be a less invasive method52, and this route is not only
well suited to multiple injections over an extended time
period, but also by using an intrathecal catheter, the treatment can be administered closer to the injury site, thereby
increasing the local concentration of MSCs. In our study,
we applied MSCs IT since our previous study using intraparenchymal injections of rat MSCs into a balloon compression model of SCI resulted in a similar recovery as
that seen in animals following intrathecal application5,7.
It is also widely accepted that the effect of MSCs is

FACING PAGE
Figure 3. Histological and immunohistochemical analysis 2 months after SCI. (A) The extent of spared white (a1) and gray (a2) matter
was determined 2 months after SCI in rats treated with saline or stem cells (MSC, SPC-01, and iPSC-NP). CV (a3 and GM) was used
for gray matter staining, while Luxol blue was used to stain the white matter (a3 and WM). Both the WM/GM surface areas were calculated according to the example on an illustrative image (a3). All implanted cells had a positive impact on tissue sparing in the WM/GM
of the injured spinal cord. However, only the iPSC-NP group showed a statistically significant preservation of spinal tissue. (B) The
effect of implanted MSCs, SPC-01, and iPSC-NP cells on glial scar formation, showing the area of astrogliosis surrounding the main
cavity as a percentage of the total tissue area (b1, b2) and the average number of protoplasmic astrocytes per section (b3, b4) around the
central lesion cavity 9 weeks after SCI. Illustrative images show GFAP-CY3 staining of the glial scar (b2) and protoplasmic astrocytes
(b4). Scale bars: 500 µm (b2, b4). Both neural precursors reduced glial scaring and the number of protoplasmic astrocytes, whereas
MSCs modulated the distribution of glial scarring and only mildly reduced it. (C) The effect of implanted MSC, SPC-01, and iPSC-NP
cells on axonal sprouting (c1). The numbers of GAP43+ fibers (15 sections per rat) are presented as percentages relative to the number
of positive fibers following saline treatment (set to 100%). Illustrative image of a GAP43+-labeled section (c2) with grafted cells.
Illustrative image of positive nuclear staining for Ku80, indicating cells of human origin (c3); arrows show GAP43+ fibers. Scale bars:
500 µm (c2), 20 µm (c3). *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus SPC-01; ¤p < 0.05 versus iPSC-NPs. For
p values of (A)–(C), see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_documents.html. MSC, mesenchymal stem cell; iPSC-NPs, human induced pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord
injury; GM, gray matter; WM, white matter; GFAP-CY3, glial fibrillary acidic protein cyanine 3; GAP43, growth-associated protein
43; HuNu, human nuclei.
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mainly paracrine, and the cells do not differentiate into
neural cells9, so there is no necessity to have them grafted
into the parenchyma from the point of functional integration. In addition, the intrathecal application of MSCs
has often been used in recent clinical trials53–55 and is less
invasive for patients. Moreover, the intrathecal application of MSCs in an animal model of amyotrophic lateral
sclerosis (ALS) prolonged life span, reduced apoptosis, and preserved the number of motoneurons and their
perineural nets56. On the other hand, the administration of
iPSC-NPs into the intrathecal space of lesioned rats had
much less effect when compared with intraspinal injection57. Moreover, NPs can differentiate into neural cells,
which can contribute to spinal cord repair. Therefore,
an injection into the spinal parenchyma was chosen for
both NPs.
In correspondence with our results, several studies
have shown that the subacute grafting of MSCs5,7,58,59,
iPSC-NPs23,28, or NPs derived from either fetal tissue or
ESCs17,18,26,60,61 leads to the improvement of locomotor
recovery. However, the mechanisms underlying the cells’
effects on locomotor recovery may vary depending on
the methods and approaches utilized25. In our study, the
highest behavioral scores were observed in the iPSC-NPtreated animals when compared not only to saline-treated
animals but also to other cell-treated groups. This outcome was observable in the basic and advanced locomotor settings. In contrast to the other treatment groups, the
iPSC-NP-treated rats extended occasional weight support at 9 weeks after SCI. Surprisingly, the high effect on
locomotor recovery was also observed in the MSC group.
Since the rapid recovery in all stem cell-treated animals
was observed within weeks after grafting, the impact of
stem cell treatment was caused by a paracrine effect in all
three types of cells (Fig. 2A–C).
The significant paracrine effect following the intraspinal grafting of both types of NP cells was most likely
due to their ability to robustly survive for the entire
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experimental period in conjunction with the maturation and differentiation of these cells, which provided a
continuous supply of new cells to the injured host tissue. These findings are in agreement with those of other
authors19,23,24,26,28,36. Furthermore, the ability of iPSC-NPs
to differentiate into a neuronal phenotype was clearly
evidenced (Fig. 1); yet on the other hand, clusters of
grafted SPC-01 cells formed structures resembling dense
clouds, with only a few host neurofilaments penetrating
the graft. These cells differentiated mainly into astrocytes
and displayed less communication with the tissue, as
observed previously19,26. It is important to note that at the
end of this study, the implanted NPs were only partially
matured, since the full maturation of human cells requires
a longer period.
In our study, in a time period matching the MSC survival period after implantation, elevated levels of endogenous VEGF, CNTF, and FGF2 were found. Increased
levels of VEGF are tightly connected with angiogenesis,
which is highly desirable for vitalizing lesioned tissue62,63,
and CNTF is a promising factor in the treatment of SCI,
with a strong neuroprotective effect in both the CNS and
also the peripheral nervous system (PNS)64. The presence
of CNTF promotes the differentiation and maturation of
oligodendrocyte precursor cells into oligodendrocytes.
Additionally, CNTF promotes mature oligondendrocyte
survival. Increased CNTF levels may thus serve to
improve remyelination after SCI65,66. In our study, the
intrinsic CNTF expression was significantly lower in
the iPSC-NP-implanted group when compared to MSCtreated animals. Together with other elevated growth factor levels found in the rats treated with MSCs, this could
be one of the reasons why, despite worse results in other
analyses, MSC-treated animals exhibited some of the
improvement in locomotor function seen in the iPSC-NPtreated group.
Recently, the strategies using MSCs in experimental treatment of CNS injuries and degenerative diseases

FACING PAGE
Figure 4. Effect of stem cell implantation on the inflammatory response and the gene expression of factors related to recovery after
SCI. (A) Relative expression of macrophage-related genes (M1-CD86, IRF5; M2-CD163, MRC1) in response to grafted MSCs,
SPC-01, and iPSC-NP cells 10 and 28 days after SCI, demonstrating that the most significant changes were evident following MSC
treatment, when IRF5 upregulation was observed 10 days after SCI. The expression levels measured in saline-treated rats were set to 0.
(B) Relative gene expression of factors related to the recovery process in response to grafted MSCs, SPC-01, or iPSC-NP cells 10 days
(b1), 28 days (b2), and 2 months (b3) after SCI. The expression levels in saline-treated rats were set to 0. (C) The levels of cytokines
and chemokines related to inflammation are presented following stem cell treatment 10 (c1), 14 (c2), and 28 (c3) days after SCI, which
correspond to 3, 7, and 21 days after implantation. The levels measured in animals with no lesion were set to 100% as indicated by a
horizontal line in the graphs. *p < 0.05 versus saline; #p < 0.05 versus MSCs; •p < 0.05 versus SPC-01; ¤p < 0.05 versus iPSC-NPs. For
p values of (A)–(C), see http://www.iem.cas.cz/en/research/departments/tissue_culture/supplementary_documents.html. MSC, mesenchymal stem cell; iPSC-NP, human induced pluripotent stem cell-derived neural precursors; SPC, spinal fetal cell; SCI, spinal cord
injury; IRF5, interferon regulatory factor 5; MRC1, mannose receptor C type 1; SORT1, sortilin 1; FGF, fibroblast growth factor;
OLIG2, oligodendrocyte transcription factor 2; GAP43, growth-associated protein 43; GFAP, glial fibrillary acidic protein; VEGF,
vascular endothelial growth factor; CNTF, ciliary neurotrophic factor; BDNF, brain-derived neurotrophic factor; NGF, nerve growth
factor; NT-3, neurotrophin-3; MIP, macrophage inflammatory protein; TNF-a, tumor necrosis factor a; RANTES, regulated on activation, normal T-cell expressed and secreted.
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have focused on MSC-produced secretomes, instead of
cell therapy itself 67. These secretomes are defined by
specific conditions of cultivation, and the effect of their
application could be different than the use of MSCs68–70.
This opens up new possibilities for combinatory therapies based on MSC secretomes as a conditional pretreatment for NP implantation71. Despite these tendencies, the
majority of preclinical investigations and clinical trials
are still using a cellular approach.
In most cases, the improvements in locomotor or sensory deficits can be correlated with the preservation of
WM/GM after SCI72–74. MSCs have been described as
immunomodulatory and proregenerative. Their paracrine effect (secretome) has proven to be beneficial in
CNS regeneration67,75. In our study, the weaker effect
on tissue sparing observed in MSC-treated animals was
perhaps due to the absence of MSCs in the tissue parenchyma, thus reflecting a purely paracrine effect as the
MSCs never made direct contact with the host tissue. On
the other hand, both types of NPs, which were directly
injected into the lesion, displayed robust survival in conjunction with the maturation and differentiation of these
cells, suggesting their involvement in the partial reconstruction of damaged tissue, which was also reflected by
the extent of spared WM/GM, more effective glial scar
modulation, and robust axonal sprouting, when compared
to saline- or MSC-treated animals (Fig. 3). These findings
are in agreement with those of other authors19,23,24,26,28,36.
The tissue response to the implantation of both NPs
and MSCs in terms of up- or downregulated expression
levels of genes of interest correlates with the observed
differences in glial scar remodulation (GFAP expression
vs. GFAP-CY3 staining) and tissue sparing (Casp3) after
SCI, where the most contradictory effects were observed
between the iPSC-NP and MSC groups. The intrinsic
growth factor production in the NP-treated rats 2 months
after SCI (BDNF, VEGF, and NGF), even though not
significantly higher than saline-treated animals, showed
a long-term stable trend toward upregulation, which
might explain the superior impact of both types of NPs
on tissue modulation.
The macrophage response reflects the type of immune
response after SCI. The ratio of M1/M2 macrophages
after injury is thought to reflect the balance of the pro-/
anti-inflammatory response. This balance may result in
the increased integration of implanted cells, influence
their migratory abilities, and lead to enhanced recovery
after SCI76. The attenuation of this balance by the application of stem cells77,78 or immunomodulatory molecules79,80
is currently of great interest. In our study, the M1/M2
macrophage gene expression profile after SCI in the celltreated animals was slightly shifted toward M2 specific,
which might be associated with the observed differences
in tissue sparing as well as glial scar formation.
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In this study we also evaluated the levels of cytokines
in response to stem cell grafting. The immune response
of the spinal tissue can differ from the systemic response
and can provide relevant answers to questions regarding
cell survival and the route of application. The most profound changes in the immunologic response to implanted
stem cells were seen in the levels of MIP-1a, TNF-a,
RANTES, IL-1 b, IL-4, IL6, and IL12.
The reduction of MIP-1a and RANTES was most pronounced in the SPC-01 and iPSC-NP groups when compared to both control and MSC-treated rats. The MIP-1a
has been implicated in the phagocytosis of myelin after
SCI and is a reliable marker of inflammation81, and the
reduction of RANTES using the anti-inflammatory compound curcumin has been demonstrated to decrease the
size of the lesion cavity82, increase neuronal viability, and
decrease cell death83. The response of both NPs nicely
reflects their impact on tissue preservation and axonal
sprouting. TNF-a has long been used as a target for antiinflammatory therapy. In SCI, TNF-a induces apoptosis
via an NF-kB-dependent mechanism as well as a mitochondrial pathway regulated by the B-cell lymphoma 2
(BCL-2) family protein, Bax84. Inhibitors of TNF-a in
the rat model of SCI have been proven to be an important cofactor for successful therapy85. In our study, the
strongest effect on TNF-a was observed in the iPSC-NP
group. Therefore, our results show that iPSC-NPs may be
the most potent stem cell population, given that they most
strongly suppressed TNF-a. MSCs have been described
to suppress TNF-a levels after neuronal damage78. In
our study, this effect was also transiently achieved in the
MSC-treated animals.
The levels of IL-1b distinguish the two neural precursor populations from each other, since the levels in the
SPC-01-treated group were significantly higher at day 14
when compared to the control groups, while these levels
remained unchanged and below control values in the
iPSC-NP group. The IL-1b levels in the MSC group were
unchanged throughout the study. IL-1b has been implicated as a proinflammatory cytokine, whose inhibition
may prove to be beneficial in SCI86. The levels of IL-1b
in the MSC- and saline-treated animals remained undistinguished throughout the study. On the other hand, the
increased IL-1b level in the SPC-01-treated group (day 14),
and the initial decreased levels in iPSC-NP group when
compared to the saline-treated animals, may partially
reflect the impact of their origin and correlate to recovery
after SCI.
IL-4 has been proposed to play an anti-inflammatory
role. Therefore, the increase in IL-4 levels at day 14 in
both the SPC-01 and iPSC-NP groups may be beneficial
and promote recovery. Specifically, IL-4-mediated arginase may promote recovery and reduce inflammation87.
When IL-4 was neutralized in a rat model of SCI, more
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extensive cavitation was noted 4 weeks after injury88.
Therefore, increased levels of IL-4 in the SPC-01 and
iPSC-NP groups, as observed at days 14 and 28 in our
study, may contribute to neuroprotection, leading to the
reduction of secondary injury or gliosis. In MSC-treated
animals, 10 and 14 days after SCI, a decrease in IL-4 was
observed when compared with both saline- and NP-treated
rats. This is in agreement with elevated IRF5 and MRC1
RNA levels following macrophage stimulation.
IL-6 remains a cytokine with dual functions. On the
one hand, it has been demonstrated to modulate the
immune response by increasing inflammation after SCI.
High levels of IL-6 can shift NSC differentiation toward
astrocytes rather than neurons, thus promoting glial scar
formation89. Additionally, suppression of IL-6 levels
reduces secondary injury by reducing inflammatory cell
infiltration90 and may result in improved recovery after
SCI91. On the other hand, a mild level of IL-6 is important
for preserving neurogenesis and neuroprotection following CNS injuries92,93. Moreover, IL-6 has been shown to
inhibit voltage-gated sodium channel currents, indicating
a potentially neuroprotective role against excitotoxicity94. In our study, MSCs partially decreased IL-6 levels,
while high levels of IL-6 were observed in the SPC-01
and iPSC-NP groups. Nevertheless, based on our observations, we believe that IL-6 remains a cytokine with
dual functions. IL-12p70 may play an anti-inflammatory
role, as its levels have been shown to decrease after SCI95
(Fig. 4). Targeted administration of IL-12 has been shown
to induce remyelination and de novo neurogenesis96
and partially prevents T-mediated demyelination97 after
neuronal damage and neurodegeneration. This evidence
suggests that increased IL-12p70 levels may play an antiinflammatory role and could be desirable after SCI, as
seen in the SPC-01 and iPSC-NP groups.
CONCLUSION
In our experimental setting, and taking into consideration two different routes of application, the use of
iPSC-NPs to treat a balloon compression SCI positively
affected the majority of studied factors involved in spinal
cord regeneration, such as glial scar formation, axonal
sprouting, tissue sparing, and cytokine levels. The cumulative effect resulted in better performance in advanced
locomotor tests (flat beam test and rotarod) requiring better movement coordination. The application of SPC-01
cells, despite their long-term survival and effect on axonal
sprouting, has not shown the potential of iPSC-NPs on
behavioral recovery. On the other hand, the implantation
of MSCs, despite their limited survival period, led to a
significant improvement in locomotor abilities, which
might be connected with their initial effect on intrinsic
growth factor production and suppression of the immune
response. Strategies to prolong MSC survival and to
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extend their effect on injured tissues by repeated application should be taken into account in future studies. To
fully support the potential of iPSC-NPs for SCI treatment, the cells should be prepared by techniques that do
not require viral integration.
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